Labcorp (LH) stock fell by 1.45% likely due to negative developments regarding its spun-off subsidiary, Fortrea Holdings (FTRE), which announced disappointing financial performance and overestimated revenue projections for its 2025 targets.

Labcorp (LH) stock fell by 1

Labcorp Holdings Inc. (NYSE: LH) recently saw a slight decline in its stock price by 0.06%, despite positive adjustments in earnings estimates by investment analysts following their earnings report, which exceeded expectations. The reason for the stock's decrease could be attributed to overall market fluctuations or profit-taking from investors following the earnings report rather than any negative news about the company.

Labcorp Holdings Inc

Labcorp (NYSE:LH) stock declined by 1.16%, closing at $261.15, following mixed analyst ratings, including a downgrade from HSBC Global Research to a "hold" rating, despite a generally positive quarterly earnings report that beat expectations. 

The stock's decline could be attributed to the downgrade from a strong buy to a hold rating by HSBC and some analysts expressing caution, despite the company's strong earnings performance.

Labcorp (NYSE:LH) stock declined by 1

Labcorp (LH) stock dipped by 1.16% amid a backdrop of legal troubles related to Fortrea Holdings, its recently spun-off subsidiary, which posted disappointing financial results and suggested its revenue projections were overestimated, raising concerns about Labcorp's past business dealings and future outlook.

Labcorp (LH) stock dipped by 1

Labcorp (LH) stock experienced a decline of 1.16% despite recent upward revisions of its target price by analysts, partly due to a downgrade from HSBC Global Research, which changed its rating from "strong-buy" to "hold."

Labcorp (LH) stock experienced a decline of 1

Labcorp (LH) stock fell by 1.16% likely due to investor concerns stemming from a class action lawsuit alleging that Fortrea Holdings, a company spun off from Labcorp, misled investors, which may have negatively impacted Labcorp's market perception.

Labcorp (NYSE: LH) stock decreased by 1.16% despite positive earnings results and a raised price target from some analysts, potentially due to mixed signals from recent analyst ratings and insider selling activity.

Labcorp (NYSE: LH) stock decreased by 1

Labcorp (LH) stock saw a 6.86% increase, likely due to positive investor sentiment following a recent class action lawsuit announcement against Fortrea Holdings, a spinoff of Labcorp, which highlighted potential financial issues but also reinforced Labcorp's strategic position.

Labcorp (LH) stock saw a 6

Labcorp (LH) stock rose by 6.86% due to favorable market conditions and strategic interest in autoimmune diagnostics, particularly linked to Exagen Inc.’s innovative offerings and potential acquisition appeal.

Labcorp (LH) stock rose by 6

Labcorp (LH) stock rose 6.86% amid optimism regarding a potential U.S.-Europe trade deal and overall positive sentiment impacting global markets. The increase in Labcorp's stock is likely reflective of broader investor confidence stemming from favorable trade negotiations and developments in business conditions.

Labcorp (LH) stock rose 6

Labcorp (LH) stock rose by 6.86% last night, attributed to strong market performance and possibly positive investor sentiment following recent company developments or broader market trends.

Labcorp (NYSE: LH) stock rose by 6.86% following a significant increase in institutional investments, particularly from Allianz Asset Management GmbH, which boosted its holdings by 107.0% in the first quarter, indicating strong investor confidence in the company's future prospects.

Labcorp (NYSE: LH) stock rose by 6

Labcorp (LH) stock fell by 0.62% amid insider selling and mixed analyst ratings, with significant reductions in positions by company executives and a cautious analyst sentiment impacting investor confidence.

Labcorp (LH) stock fell by 0

Labcorp (LH) stock rose 3.72% likely due to investor optimism stemming from the ongoing legal activities and developments surrounding its spinoff, Fortrea Holdings Inc., despite the challenges and allegations the latter is facing in a recent class action lawsuit.

Labcorp (LH) stock rose 3

Labcorp (LH) stock rose 3.72% possibly due to investor optimism, as it is indirectly related to the legal troubles of its former subsidiary, Fortrea Holdings, which has been embroiled in a lawsuit for alleged securities fraud, potentially shifting focus back to Labcorp's strong underlying performance.

Labcorp (NYSE: LH) stock fell by 0.28% due to insider selling, with executives reducing their holdings, which may have raised concerns among investors about the company's outlook.

Labcorp (NYSE: LH) stock fell by 0

Labcorp (LH) stock declined by 0.28% following a reduction in its price target from UBS Group, which lowered it from $284.00 to $282.00, while other analysts also downgraded their ratings or price targets for the stock.

Labcorp (LH) stock declined by 0

Labcorp (LH) stock declined by 1.42% following the announcement of a class action lawsuit against Fortrea Holdings Inc., a company spun off from Labcorp, which is alleged to have misled investors about its operations and financial conditions.

Labcorp (LH) stock declined by 1

Labcorp (LH) stock rose by 0.51% as the company prepares to release its Q2 2025 earnings on July 24, with positive sentiment driven by recent earnings performance that beat analyst expectations and raised target price estimates from analysts.

Labcorp (LH) stock rose by 0

Labcorp (LH) stock was up 0.13% likely due to the positive market sentiment surrounding Onconetix, Inc.'s merger agreement with Ocuvex Therapeutics, enhancing the potential for growth and innovation in ophthalmic therapeutics that could benefit Labcorp's diagnostic testing and partnerships.

Labcorp (LH) stock was up 0

The article discusses a lawsuit filed against Fortrea Holdings Inc. for alleged securities fraud following its spin-off from Labcorp, which may have contributed to Labcorp's stock rising by 0.13% as investors potentially reassess the impact of this legal action.

The article discusses a lawsuit filed against Fortrea Holdings Inc

Labcorp (LH) stock declined by 1.66% due to the fallout from its former subsidiary, Fortrea Holdings, which reported disappointing financial results and overestimated its revenue contributions, leading to decreased investor confidence in Labcorp's business relationships and financial prospects following the spin-off.

Labcorp (LH) stock rose 0.07% amidst legal developments involving Fortrea Holdings, the company spun off from Labcorp, which is facing a lawsuit for alleged securities fraud, likely causing investor interest or confidence in Labcorp due to its ongoing connection with Fortrea.

Labcorp (LH) stock rose 0

Labcorp (LH) stock fell by 1.58% after analysts issued mixed ratings, with Barclays maintaining a cautious stance and HSBC downgrading the stock, leading to uncertainty among investors.

Labcorp (LH) stock fell by 1.58% after Leerink Partners downgraded their earnings per share estimates for 2027, predicting a decrease from $19.91 to $19.74, signaling concerns regarding the company's future financial performance.

Labcorp (NYSE:LH) stock fell by 1.58% likely due to mixed earnings estimates and varying analyst ratings, including a downgrade from HSBC, despite a recent increase in Q2 earnings projections by Leerink Partners.

Labcorp (NYSE:LH) stock fell by 1

Labcorp (LH) stock fell by 2.1% following legal troubles associated with Fortrea Holdings, a company spun off from Labcorp, which is facing a lawsuit for allegedly overstating cost savings and revenue projections, leading to a significant decline in Fortrea's stock price and investor sentiment.

Labcorp (LH) stock fell by 2

Labcorp (LH) stock fell by 2.1% following insider selling by executives, which may signal concern about the company's future performance, despite recent positive quarterly earnings.

Labcorp (LH) stock experienced a slight decline of -0.16% potentially due to the negative impacts of a securities fraud lawsuit against its spun-off company, Fortrea Holdings Inc., which has faced significant financial challenges and public scrutiny regarding overstated cost savings and revenue expectations since its separation from Labcorp.

Labcorp (LH) stock experienced a slight decline of -0

Labcorp (LH) stock decreased by 0.16% amidst broader market concerns related to ongoing class action lawsuits targeting several companies, potentially reflecting investor caution and market reaction to legal risks associated with those firms.

Labcorp (LH) stock decreased by 0

Labcorp (LH) stock declined by 1.54% due to insider selling by executives and a mixed reaction from analysts regarding its performance and ratings, despite showing a slight increase in quarterly revenue.

Labcorp (LH) stock fell by 1.54% primarily due to significant institutional selling, particularly by Vontobel Holding Ltd., which reduced its stake by 43.5%, indicating a potential loss of investor confidence.

Labcorp (LH) stock experienced a decline of 1.54% due to negative market sentiment and broader market trends affecting healthcare stocks, not specifically mentioned but generally influenced by uncertainty in the financial performance of companies in the sector.

Labcorp (NYSE: LH) stock fell by 1.54% primarily due to institutional investors adjusting their positions, including significant insider selling, which raised concerns about the company's future performance despite previously reported strong earnings.

Labcorp (NYSE: LH) stock fell by 1

Labcorp (LH) stock experienced a 0.73% increase due to its association with the spin-off of Fortrea Holdings Inc., which is currently facing a class-action lawsuit for securities fraud, signaling investor interest in Labcorp’s stability amidst Fortrea's struggles.

Labcorp (LH) stock experienced a 0

Labcorp (LH) stock rose 0.73% due to increased investments from institutional investors, as evidenced by Amalgamated Bank raising its position and other firms significantly boosting their holdings.

Labcorp (LH) stock declined by 1.61% following the revelation of significant overstatements in the cost savings and revenue projections by its spun-off company, Fortrea Holdings, which is facing a lawsuit for securities fraud and reported disappointing financial results.

Labcorp (LH) stock declined by 1.61% as investors reacted to mixed earnings performance and selling by company executives, despite several hedge funds increasing their holdings in the company.

Labcorp (LH) stock was up 0.67% due to the overall market sentiment and potential positive developments in its operational performance following the spin-off of Fortrea Holdings Inc., which has sparked investor interest.

Labcorp (LH) stock rose by 1.4% due to positive changes in analysts' ratings and increased institutional investment in the company, highlighted by several firms raising their price targets and maintaining or upgrading their ratings on the stock.

Labcorp (LH) stock rose by 1

Labcorp (LH) stock declined by 0.66% due to concerns over Fortrea Holdings Inc., a company spun off from Labcorp, which faced a lawsuit for allegedly overstating cost savings and revenue expectations in its transition services agreements, leading to significant stock price drops after negative financial reports.

Labcorp (NYSE:LH) stock dropped by 0.66% following a report that included a $275 target price from Barclays, despite other analysts expressing more favorable ratings and price targets for the medical research company, suggesting market volatility or investor sentiment could be affecting stock performance.

Labcorp (NYSE:LH) stock dropped by 0

Labcorp (NYSE: LH) stock increased by 0.57% following recent analyst ratings upgrades and positive quarterly earnings that surpassed expectations, despite some insider selling and a slight reduction in institutional ownership.

Labcorp (NYSE: LH) stock increased by 0

Labcorp (NYSE: LH) stock increased by 0.57% due to significant investment by Wealth Enhancement Advisory Services LLC and other institutional investors, alongside positive adjustments in target prices from multiple brokerages signaling confidence in the company's performance.

LabCorp (LH) stock experienced a slight increase of 0.57% due to overall positive market sentiment, possibly influenced by legal developments and class action reminders regarding various companies, including Fortrea Holdings, which is linked to LabCorp, suggesting ongoing investor interest and attention in the sector.

LabCorp (LH) stock experienced a slight increase of 0

Labcorp (LH) stock increased by 0.57% following the news of a lawsuit filed against Fortrea Holdings Inc., a company spun off from Labcorp, for potential securities law violations, highlighting the implications of the spin-off on investor sentiment. 

The increase in Labcorp's stock may be attributed to a possible positive investor sentiment towards Labcorp, as it is not directly implicated in the lawsuit, thus suggesting stability or value in Labcorp's operations despite issues faced by Fortrea.

Labcorp (LH) stock increased by 0

Labcorp (LH) stock recently increased by 0.57%, possibly due to investor response to ongoing developments related to its spin-off of Fortrea Holdings, which has faced challenges with financial forecast discrepancies leading to a class action investigation that might ultimately shed light on Labcorp’s own business performance and prospects.

Labcorp (LH) stock recently increased by 0

Labcorp (LH) stock declined by 0.32% recently amidst various changes in institutional holdings and insider sales, highlighting potential investor concerns about ownership dynamics and market performance. The decline may be influenced by recent insider selling, fluctuations in institutional investments, and mixed analyst ratings, despite the company beating earnings estimates in its latest report.

Labcorp (LH) stock was down by 0.32% following the announcement of a class action lawsuit against its spin-off company, Fortrea Holdings, which raised concerns about Fortrea's financial outlook, including overstated revenue expectations and EBITDA margins, thereby negatively impacting investor sentiment.

Labcorp (LH) stock was down by 0

Labcorp (LH) stock increased by 0.19% likely due to the ongoing legal issues faced by Fortrea Holdings Inc., which was spun off from Labcorp, prompting investor interest in Labcorp's potential liability and performance amidst these developments.

Labcorp (LH) stock rose by 0.75% likely due to institutional investors increasing their stakes and positive analyst ratings, suggesting confidence in the company's performance and future prospects.

Labcorp (LH) stock declined by 1.71% due to ongoing class action lawsuits against its spin-off company Fortrea Holdings Inc., which revealed disappointing financial projections that raised concerns about Labcorp's business prospects.

Labcorp (LH) stock increased by 1.09% likely due to investor sentiment remaining stable amidst the ongoing legal issues faced by Fortrea Holdings Inc., which Labcorp spun off; the lawsuit highlights potential problems for Fortrea, but does not directly implicate Labcorp.

Labcorp (LH) stock increased by 1

Labcorp (LH) stock rose by 1.09% due to positive market sentiment likely influenced by the ongoing class action lawsuit involving its former subsidiary, Fortrea Holdings Inc., which reflects investor interest in the outcomes of legal proceedings and potential implications for Labcorp's valuation.

Labcorp (LH) stock was down 0.2% after several brokerages, while raising target prices on the stock, indicated a mixed sentiment, with some analysts downgrading their ratings, which may have contributed to the decline.

Labcorp (LH) stock was down 0

Labcorp (LH) stock decreased by 0.2% primarily due to a recent shift in analyst ratings and insider selling, which may have contributed to a cautious sentiment among investors, despite strong earnings and revenue growth reported in the last quarter.

Labcorp (LH) shares saw a slight decline of 0.2% recently, despite being rated a "Moderate Buy" by analysts, due to a downgrade from Wall Street Zen and insider stock sales, particularly from a director.

Labcorp (LH) shares saw a slight decline of 0

Labcorp (LH) stock rose 0.65% following an SEC filing that revealed Board Member Kerrii B. Anderson sold 500 shares, which is often interpreted by investors as a potential positive signal for the company's future performance.

Labcorp (LH) stock rose by 0.65% amid news of a lawsuit filed against Fortrea Holdings Inc. for alleged securities law violations, which may have positively impacted Labcorp's stock due to its association with Fortrea, a company it spun off.

Labcorp (LH) stock rose 1.42% due to increased institutional investment, with several firms acquiring or boosting their stakes, alongside positive earnings reports that exceeded analyst expectations.

Labcorp (LH) stock rose 1

Labcorp (LH) stock rose by 1.42% likely due to positive investor sentiment amidst legal proceedings involving class actions against its former subsidiary, Fortrea Holdings, which may have reassured investors about Labcorp's stability and market position.

Labcorp (LH) stock rose by 1.42% due to the ongoing developments regarding the class action lawsuit against Fortrea Holdings Inc., which Labcorp spun off, reflecting investor sentiment and potential implications for Labcorp’s own business following these legal proceedings.

Labcorp (LH) stock rose by 1.42% amidst a lawsuit filed against Fortrea Holdings, a company it spun off, for allegedly overstating potential cost savings and revenue post-spin, which affected Fortrea’s stock negatively, potentially increasing investor confidence in Labcorp.

Labcorp (LH) stock rose by 0.69% due to increased institutional investment, positive analyst ratings upgrades, and better-than-expected earnings performance, alongside a stable dividend announcement.

The article discusses a lawsuit filed against Fortrea Holdings Inc. for potential federal securities law violations following its spin-off from Labcorp, with Labcorp's stock (LH) rising 0.72% likely due to positive market sentiment or external factors unrelated to the litigation affecting Fortrea.

Labcorp (LH) stock rose by 0.72% due to its previous association with Fortrea Holdings, which recently faced legal challenges and reported disappointing financial forecasts, leading to increased investor interest in Labcorp as a potentially more stable investment.

Labcorp (LH) stock increased by 1.54% amidst ongoing legal proceedings related to its spinoff company, Fortrea Holdings Inc., which is facing a class action lawsuit for allegedly misleading investors about its financial performance, highlighting ongoing interest and confidence in Labcorp’s broader business amid Fortrea's challenges.

Labcorp (LH) stock increased by 1.07% as various institutional investors adjusted their stakes, with analysts boosting their price targets and ratings for the company, indicating bullish sentiment in the market.

Labcorp (LH) stock fell by 0.27%, influenced by the State of Wyoming significantly reducing its stake in the company by 82.2%, along with various insider sales indicating potential concerns among institutional investors.

Labcorp (LH) stock experienced a slight decline of 0.27% due to substantial selling by Man Group plc, which reduced its holdings by 87.4%, alongside other institutional investors adjusting their positions.

Labcorp (LH) stock experienced a slight decline of 0

Labcorp (LH) stock experienced a decline of -3.77% following a mix of institutional selling and recent insider trades that may have raised concerns among investors regarding its future performance and liquidity.

Labcorp (LH) stock experienced a decline of -3

Labcorp (LH) stock rose 0.11% after receiving a "Moderate Buy" rating from analysts, with several increasing their price targets based on positive earnings reports and overall growth expectations in the medical testing services sector.

LH

Latest News & Analysis